12:18 PM EDT, 03/12/2024 (MT Newswires) -- Autolus Therapeutics ( AUTL ) said Tuesday its Nucleus manufacturing facility in Stevenage received manufacturer's importation authorization and good manufacturing practices certificate from the Medicines and Healthcare Products Regulatory Agency.

The agency inspected the facility in February and has issued two new licenses to cover commercial and clinical manufacturing, according to the company.

The authorization allows Autolus to manufacture products for global commercial and clinical supply from the Nucleus facility starting Monday, according to the company.

Autolus shares were down about 1.2% in recent trading.

Price: 5.35, Change: -0.07, Percent Change: -1.20